HSE position on antiretroviral therapy for all people living with HIV. by unknown
 09/08/2017                   HSE Sexual Health & Crisis Pregnancy Programme            Page 1 of 7 
HSE Position 
  on Antiretroviral Therapy 
  for all people living with HIV 
Background 
The overarching vision of Ireland’s first sexual health strategy1, launched in October 2015, is to 
improve sexual health and wellbeing and reduce negative sexual health outcomes. With respect to 
HIV, this calls for actions to reduce the number of new infections and ensure the health and 
wellbeing of those living with HIV.  
These requirements are reflected in two of the priority actions in the strategy, specifically: 
“Assess, develop and implement guidance on (STI and) HIV testing in various settings to 
improve access and ease of testing and to include guidance on home based testing and the 
use of point of care HIV testing.” 
and  
“Develop and implement guidance to support the appropriate use of antiretroviral therapy 
in HIV prevention.” 
Antiretroviral therapy can be used for HIV prevention by treating those with established infection, 
known as Treatment as Prevention (TasP); through administration to those at risk of infection (Pre 
exposure prophylaxis, PrEP); or administration to those who may have been exposed to infection 
(Post exposure prophylaxis, PEP). National guidelines for the use of PEP have been in place since 
20122. There are no national guidelines for the use of TasP and PrEP.  
In Ireland, in accordance with the Infectious Diseases Regulations, there is no charge to an individual 
for the treatment of HIV.3 4 
This document sets out the current situation and the HSE position on the use of antiretroviral 
therapy (including TasP) for HIV infected people attending HIV services in Ireland.  
Evidence and International Guidelines  
Since highly active antiretroviral therapy (HAART) first became available in the mid 1990’s enormous 
progress has been made in the treatment of people infected with HIV such that, for many, life 
expectancy is similar to that of the general population. Given the benefits of early initiation of 
antiretroviral therapy 3 5 6 7 over a range of economic settings, for those diagnosed with HIV, 
international guidelines recommend that antiretroviral therapy is offered to all people living with HIV 
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regardless of immunological status (CD4 count) 5  6  7  8. Previous guidelines have recommended 
initiation of antiretroviral therapy at various clinical and immunological (CD4 count) thresholds. 
In addition, there is robust clinical trial8 and cohort data9 demonstrating the effectiveness of 
antiretroviral therapy in preventing onward HIV transmission (TasP). International guidelines for the 
management of HIV now recommend TasP10 11 12 13.  
Guideline recommendations, including the strength of the recommendations on the timing of 
antiretroviral therapy initiation for those diagnosed with HIV are shown in Appendix 1.  
Thus, current evidence indicates that all individuals living with HIV should be offered antiretroviral 
therapy, from a population perspective to reduce incident HIV infections (TasP) and, from an 
individual perspective to reduce morbidity and improve life expectancy.  
In October 2014, UNAIDS issued the “90:90:90” statement. This is an ambitious global treatment 
target, to help end the AIDS epidemic. The target is that by 2020, 90% of all people living with HIV 
will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained 
antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral 
suppression.14 
Current HIV care and practice in Ireland  
In Ireland, HIV care is currently provided in nine hospital settings. Adult care is provided in Cork (Cork 
University Hospital), Dublin (Beaumont Hospital, Mater Misericordiae University Hospital, St. James’s 
Hospital, St. Vincent’s University Hospital), Galway (Galway University Hospital) and Limerick 
(Limerick University Hospital). Paediatric HIV care is provided in Dublin at Temple St. University 
Hospital and Our Lady’s Children’s Hospital.  
In 2010, a national study of six adult HIV outpatient services found that of 3202 patients accessing 
care, 80% were on antiretroviral therapy of whom 87% had evidence of virological control (HIV-RNA 
levels <50cpm)15.  More recent results from personal communication and audits carried out at 
individual services between 2014 and 2016, indicate that between 92 and 100% of patients retained 
in care are on antiretroviral therapy with virological suppression rates of >/=90%.16 17.  
In June 2016 a cross-sectional study of healthcare professionals involved in the provision of HIV and 
STI care in Ireland was undertaken.  Respondents prescribing antiretroviral therapy indicated that on 
average 90% (range 70-100) of their HIV patients were in receipt of antiretroviral therapy. 
Furthermore, 95% of respondents agreed that Ireland should adopt a policy of offering antiretroviral 
therapy to all HIV-infected individuals and 92% of respondents indicated they agreed (19%) or 
strongly agreed (72%) with the statement “In general, I recommend antiretroviral therapy for HIV-
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infected patients irrespective of CD4 count” and 86% reported that they “always” or “often” 
recommended initiation of antiretroviral therapy in HIV-infected patients with CD4+ >500 
cells/mm.18  
This suggests that, in Ireland, of HIV infected individuals engaged in care, the UNAIDS target of “90% 
in receipt of sustained antiretroviral therapy” has been reached and in many instances exceeded.  
Development process 
This document was developed by the Clinical Lead in Sexual Health at the HSE Sexual Health and 
Crisis Pregnancy Programme with input, advice and review by both the Sexual Health Strategy 
Implementation and Clinical Advisory groups. The affiliation of the members of these groups is listed 
in Appendix 2 and includes community, service provider, service user and advocacy representation.  
HSE position on Antiretroviral Therapy for all HIV infected people 
The HSE recommends that all HIV infected individuals attending HIV services in Ireland are offered 
antiretroviral therapy as soon as possible and informed of the benefits of antiretroviral therapy in 
reducing HIV infectiousness (TasP) and improving their personal health.  
Implementation and Monitoring 
As outlined earlier available information suggests that the target of 90% in receipt of antiretroviral 
therapy for those attending services has already been met within existing services. Therefore this 
recommendation does not require a formal implementation plan.  
A patient information leaflet outlining this recommendation is in development. 
In order to monitor this recommendation an audit of clinical services will be undertaken in 2017. 
Further monitoring and audit will be guided by the initial audit findings with a view to annual 
assessment. This will serve to fulfill Ireland’s obligation to report on the national response to the HIV 
epidemic to the European Centre for Disease Prevention and Control (ECDC) via the “Dublin Declaration on 
Partnership to Fight HIV/AIDS in Europe and Central Asia” and to the UN General Assembly via UNAIDS/WHO.    
The first audit round will address the following: 
 Number attending HIV services over the reporting time 
 Number and proportion of those who attended over the reporting period on antiretroviral 
therapy 
 Number and proportion of those on antiretroviral therapy over the reporting period 
virologically suppressed (at <200 copies/ml and <40 copies/ml).  
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Appendix 1 
 
GUIDELINE Year 
Published 
Recommendations Grading system Strength of 
Recommendation 
British HIV 
association 
guidelines 
for the 
treatment of 
HIV-1-
positive 
adults with 
antiretroviral 
therapy19 
 
 
2015 
(2016 
interim 
update) 
1) We recommend people 
with HIV start ART. 
2) We recommend that 
individuals presenting 
with an AIDS-defining 
infection, or with a 
serious bacterial 
infection and a CD4 cell 
count. 
3) We recommend all 
individuals with 
suspected or diagnosed 
PHI are reviewed 
promptly by an HIV 
specialist and offered 
immediate ART. 
4) We recommend that ART 
is offered to all PLWH for 
the prevention of onward 
transmission.  
5) We recommend the 
evidence that treatment 
with ART substantially 
lowers the risk of 
transmission is discussed 
with all PLWH.  
6) An assessment of the risk 
of transmission to others 
should be made at 
diagnosis and 
subsequent visits. 
Modified GRADE 1A 
 
1B 
 
 
 
 
 
 
1B 
 
 
 
 
 
 
1A 
 
 
 
GPP 
 
 
 
 
 
GPP 
European 
AIDS clinical 
society20 
2015 1) Symptomatic HIV disease 
(CDC B or C conditions, 
incl. tuberculosis) at any 
CD4 count 
2) Asymptomatic HIV 
infection  
 Current CD4 count < 350  
 Current CD4 count ≥ 350 
3) Treatment of Primary HIV 
Infection 
 Severe or prolonged 
symptoms  
 Neurological disease  
 Age ≥ 50 years  
 CD4 count < 350 cells/µL  
Not specified but 
indicated as 
recommended 
(R) or strongly 
recommended 
(SR) 
SR 
 
 
 
 
 
SR 
R 
 
 
SR 
 
SR 
SR 
SR 
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 Asymptomatic CD4 count 
> 350 cells/µL  
R 
Department 
of Health 
and Human 
Services 
Guidelines 
for the use of 
antiretroviral 
agents in 
HIV-1-
infected 
adults and 
adolescents21 
2016 1) Antiretroviral therapy 
(ART) is recommended 
for all HIV-infected 
individuals, regardless of 
CD4 T lymphocyte cell 
count, to reduce the 
morbidity and mortality 
associated with HIV 
infection.  
2)  ART is also 
recommended for HIV-
infected individuals to 
prevent HIV 
transmission.  
3) When initiating ART, it is 
important to educate 
patients regarding the 
benefits and 
considerations regarding 
ART, and to address 
strategies to optimize 
adherence. On a case-by-
case basis, ART may be 
deferred because of 
clinical and/or 
psychosocial factors, but 
therapy should be 
initiated as soon as 
possible. 
Rating of 
Recommendatio
ns: A = Strong; B 
= Moderate; C = 
Optional 
 
Rating of 
Evidence: I = 
Data from 
randomized 
controlled trials; 
II = Data from 
well-designed 
nonrandomized 
trials or 
observational 
cohort studies 
with long-term 
clinical 
outcomes; III = 
Expert opinion 
AI 
 
 
 
 
 
 
 
 
AI 
World Health 
Organisation 
Guideline on 
when to start 
antiretroviral 
therapy and 
on Pre-
exposure 
prophylaxis 
for HIV22 
2015 1) ART should be initiated in 
all adults living with HIV 
at any CD4 cell count 
2) As a priority, ART should 
be initiated in all adults 
with severe or advanced 
HIV clinical disease (WHO 
clinical stage 3 or 4) and 
individuals with CD4 
count ≤350 cells/mm3* 
GRADE Strong, moderate 
evidence 
 
Strong, moderate 
evidence 
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Appendix 2 
 
Implementation Group Membership Affiliations 
Organisation represented 
HSE Sexual Health & Crisis Pregnancy Programme 
HSE Public Health Departments 
HSE Health Protection Surveillance Centre (HPSC) 
HSE Primary Care 
HSE Social Inclusion 
HSE Acute Hospitals Division 
HSE Mental Health 
NGO sector 
Irish College of General Practitioners (ICGP)  
Service User Representative 
 
Clinical Advisory Group Membership Affiliations 
Organisation represented  
HSE Sexual Health & Crisis Pregnancy Programme 
HPSC, RCPI faculty of Public Health Medicine 
Public Health, RCPI faculty of Public Health Medicine 
RCPI institute of obstetricians and gynaecologists 
Society for the Study of Sexually Transmitted Infections in Ireland (SSSTDI) 
Infectious Diseases Society of Ireland (IDSI) 
Irish College of General Practitioners (ICGP) 
Clinical Microbiology (Faculty of Pathology) 
Irish Society of Urology 
Faculty of Occupational Medicine 
Nursing and Midwifery Board of Ireland 
Irish Pharmacy Union 
Irish Association of Emergency Medicine 
RCPI Faculty of Paediatrics 
RCPI Collegiate Members Committee 
Academy of Clinical Science and Laboratory Medicine of Ireland 
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